A COMPARISON OF THE EFFICACY AND SAFETY OF A BETA-BLOCKER, A CALCIUM-CHANNEL BLOCKER, AND A CONVERTING-ENZYME-INHIBITOR IN HYPERTENSIVE BLACKS
A COMPARISON OF THE EFFICACY AND SAFETY OF A BETA-BLOCKER, A CALCIUM-CHANNEL BLOCKER, AND A CONVERTING-ENZYME-INHIBITOR IN HYPERTENSIVE BLACKS
复制标题
DOI：
10.1001/archinte.150.8.1707
复制
发表时间：
1990-08-01
影响因子：
--
通讯作者：
FLAMENBAUM, W
中科院分区：
文献类型：
--
作者：
SAUNDERS, E;WEIR, MR;FLAMENBAUM, W
进行了一项双盲、正对照、强制剂量滴定研究，比较阿替洛尔、卡托普利和维拉帕米缓释片作为单药治疗黑人轻中度高血压（舒张压95 ~ 114 mm Hg）患者的疗效和安全性。共有394名患者被随机分配到三种治疗方法中的一种。在2至4周安慰剂治疗期间（基线），三组的平均血压范围为舒张100.4至100.7毫米汞柱，收缩压151.7至152.5毫米汞柱。在这些患者中，355人（其中345人有可评估的数据）完成了第一个治疗期，包括50mg /d阿替洛尔、25mg / 12小时卡托普利或240mg /d维拉帕米缓释治疗。在第二个4周的治疗期间，319例患者完成了治疗（307例可评估），其中一半患者的降压药物剂量增加，另一半继续相同剂量。目标血压被定义为仰卧舒张压低于90毫米汞柱或仰卧舒张压较预处理水平下降10毫米汞柱或更高。阿替洛尔、卡托普利和维拉帕米缓释治疗在第一次治疗期间分别与55.1%、43.8%和65.2%的时间相关，在第二次治疗期间分别与59.6%、57.1%和73.0%的时间相关。这三种药物的副作用都很小，而且具有可比性。
A double-blind, positively controlled, forced dose titration study comparing the efficacy and safety of atenolol, captopril, and verapamil sustained release as single agents in the treatment of black patients with mild to moderate hypertension (diastolic blood pressure, 95 to 114 mm Hg) was conducted. A total of 394 patients were randomized to one of the three therapies. Mean blood pressures during a 2- to 4-week placebo treatment period (baseline) ranged from 100.4 to 100.7 mm Hg diastolic and 151.7 to 152.5 mm Hg systolic for the three groups. Of the patients, 355 (of whom 345 had assessable data) completed the first treatment period, which consisted of therapy with either 50 mg/d of atenolol, 25 mg every 12 hours of captopril, or 240 mg/d of verapamil sustained release. During the second 4-week treatment period, which 319 patients completed (307 assessable), half of the patients had their antihypertensive medication increased and the other half continued the same dose. Goal blood pressure was defined as a supine diastolic pressure of less than 90 mm Hg or a 10-mm Hg or greater drop in supine diastolic blood pressure from pretreatment levels. Atenolol, captopril, and verapamil sustained release therapy was associated with goal blood pressure achievement during the first treatment period 55.1%, 43.8%, and 65.2% of the time, respectively, and during the second treatment period 59.6%, 57.1%, and 73.0% of the time. Side effects were minimal and comparable for all three drugs.